Vincent A. Miller

Oncology · 2000–2019

A researcher in the Science corpus: 32 papers; trusts 2 researchers and is trusted by 14 researchers here, as inferred from the citation graph.

Subfields

• Oncology — 247 citations into it; #498 of 1,698 by trust here, #40 by citations
• Pulmonary and Respiratory Medicine — 222 citations into it; #48 of 770 by trust here, #6 by citations

Whom Vincent A. Miller trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. William Pao
2. M. Kris

Who trusts Vincent A. Miller overall

1. William Pao
2. B. Chan
3. L. Sequist
4. Adi F. Gazdar
5. J. Baselga
6. H. Shigematsu
7. Gregory Riely

Papers from Vincent A. Miller's perspective

Ordered by how strongly the researchers Vincent A. Miller trusts endorse each paper. Same corpus, a different order for every researcher.

1. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. (Proceedings of the National Academy of Sciences of the United States of America)
2. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification (Science)
3. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. (Journal of Clinical Oncology)
4. Mutations of the BRAF gene in human cancer (Nature)
5. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. (New England Journal of Medicine)
6. Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways (Science)
7. Targeted cancer therapy (Nature)
8. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. (Cancer Research)
9. New guidelines to evaluate the response to treatment in solid tumors (Journal of the National Cancer Institute)
10. Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor* (Journal of Biological Chemistry)

Their papers

• Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing (2012) — 1,811 citations
• Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing (2013) — 2,044 citations
• KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib (2005) — 1,447 citations
• Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. (2004) — 1,775 citations
• Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. (2011) — 679 citations
• Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study (2019) — 600 citations
• Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial (2019) — 501 citations
• STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma (2018) — 1,344 citations
• Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers (2017) — 1,964 citations
• Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden (2017) — 3,045 citations
• Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. (2015) — 714 citations
• Co-occurring genomic alterations define major subsets of KRAS - mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities (2015) — 835 citations
• Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor positive breast cancer (2014) — 595 citations
• Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR TKI therapy in 155 patients with EGFR mutant Lung Cancers (2013) — 2,352 citations
• Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. (2012) — 968 citations
• Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer (2012) — 1,168 citations
• HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. (2012) — 666 citations
• International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma (2011) — 4,028 citations
• Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. (2010) — 798 citations
• Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer: Distinct natural history of patients with tumors harboring the T790M mutation (2010) — 619 citations